Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
On-demand IC351 (Cialis (TM)) enhances erectile function in patients with erectile dysfunction
Autore:
Padma-Nathan, H; McMurray, JG; Pullman, WE; Whitaker, JS; Saoud, JB; Ferguson, KM; Rosen, RC;
Indirizzi:
Univ So Calif, Keck Sch Med, Beverly Hills, CA 90212 USA Univ So Calif Beverly Hills CA USA 90212 Med, Beverly Hills, CA 90212 USA Med Affiliated Res Ctr, Huntsville, AL USA Med Affiliated Res Ctr Huntsville AL USA ted Res Ctr, Huntsville, AL USA Eli Lilly & Co, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis INUSA 46285 & Co, Indianapolis, IN 46285 USA ICOS Corp, Bothell, WA USA ICOS Corp Bothell WA USAICOS Corp, Bothell, WA USA Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA Univ Med & Dent New Jersey Piscataway NJ USA 08854 scataway, NJ 08854 USA
Titolo Testata:
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
fascicolo: 1, volume: 13, anno: 2001,
pagine: 2 - 9
SICI:
0955-9930(200102)13:1<2:OI((EE>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTERNATIONAL INDEX; CORPUS CAVERNOSUM; ORAL SILDENAFIL; NITRIC-OXIDE; RELAXATION;
Keywords:
IC351; Cialis (TM); PDE5 inhibitor; erectile dysfunction;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Padma-Nathan, H Univ So Calif, Keck Sch Med, 9100 Wilshire Blvd,East Tower,Suite 360, Beverly Hills, CA 90212 USA Univ So Calif 9100 Wilshire Blvd,East Tower,Suite 360 Beverly Hills CA USA 90212
Citazione:
H. Padma-Nathan et al., "On-demand IC351 (Cialis (TM)) enhances erectile function in patients with erectile dysfunction", INT J IMPOT, 13(1), 2001, pp. 2-9

Abstract

IC351 (Cialis(TM)) is a selective inhibitor of PDES. The efficacy and safety of on-demand dosing of IC351 in men with erectile dysfunction was assessed in a multicenter, double-blind, placebo-controlled study. One hundred seventy-nine men (mean age: 56 y) were randomized to receive placebo or IC351at doses of 2, 5, 10 or 25 mg, taken on demand over a 3-week period. The primary endpoints were change from baseline in responses to Questions 3 (Q3)and 4 (Q4) of the International Index of Erectile Function (IIEF). IC351 significantly improved IIEF Q3 scores at all doses vs placebo (P less than or equal to 0.003). IC351 also significantly improved IIEF Q4 scores in all but the 2 mg group (P less than or equal to 0.0003), No significant changesin laboratory values, ECGs, or blood pressure were observed. The most common adverse events were headache and dyspepsia. The conclusion of this studywas that on demand IC351 at doses up to 25 mg was well tolerated and significantly improved erectile function.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 03:05:08